Article information
Abstract
The current state of molecular knowledge on lung cancer demands a histological classification which goes beyond small-cell and non-small-cell carcinoma to provide support for tailored therapy in aiding in understanding of the drugs currently available.
As diagnosis and follow-up in the vast majority of lung cancer cases is based on biopsies and cytology samples, Immunohistochemical Bronchial Pulmonary Carcinoma Classification (IBPCC) is necessary to reveal the raft of characteristics available. This provides morphological support for the WHO's 1999/2004 classification, in addition to an understanding of carcinogenesis.
The immunohistochemical panel clarifies the main morphology and cytology characteristics to maintain the leading histological types as squamous cell carcinoma (high weight molecular cytokeratins/HWMC), adenosquamous carcinoma (CK7, TTF1, HWMA), neuroendocrine carcinoma (Chrg, Syn, CD56, TTF1, Ki67), adenocarcinoma (CK7, CK20, TTF1) and bring the polymorphic and pleomorphic carcinomas under a single banner of pleomorphic carcinoma (Ck7, TTF1, HWMC, VMT, Desmin, Actin) which shelters large cell carcinomas and sarcomatoid carcinomas.
Lung cancer chemotherapy will still be based on platinum and gemcitabine for the near future and the IBPCC is a simple and efficient tool for streamlining the registration of lung cancer histological characteristics in biopsies and other reduced samples to support clinical evidence and trials.
Key-words:
Bronchial-pulmonary carcinoma
immunohistochemistry
Resumo
Os conhecimentos actuais da patologia molecular do cancro do pulmão requerem outra caracterização histológica, para além de carcinoma de células pequenas e carcinoma não pequenas células para suporte da terapia personalizada e entendimento do valor real dos fármacos actualmente disponíveis.
Como o diagnóstico e seguimento clínico da maioria dos casos de cancro do pulmão se baseia em produtos de biópsia e citologia, a classificação imunoistoquímica do carcinoma broncopulmonar (IBPCC) é necessária para suporte morfológico da classificação da WHO 1999/2004, clarificando as características celulares das neoplasias e o entendimento da carcinogénese.
O painel imunoistoquímico reforça os tipos histológicos principais do carcinoma bronco – pulmonar: carcinoma epidermóide (queratinas de alto peso molecular – HWMC), carcinoma adenoscamoso (CK/ /TTF1, MWMC), carcinoma neuroendócrino (Chrg, Syn, CD56, TTF1, Ki67) e adenocarcinoma (CK7, Ck20, TTF1); as variantes do carcinoma de células grandes e do carcinoma sarcomatóide são englobados num único grupo de carcinomas pleomórficos (CK7, TTF1, HWMC, VMT, desmina, actina), onde cabe o polimorfismo e o pleomorfismo celular.
A quimioterapia do carcinoma broncopulmonar continuará baseada no platino e na gemcitabina no futuro próximo e a IBPCC será uma ferramenta simples e eficiente para o registo das características e tipos histológicos do carcinoma do pulmão presentes nas biópsias e amostras citológicas para suporte da evidência clínica e dos ensaios farmacêuticos.
Palavras-chave:
Carcinoma broncopulmonar
imunoistoquímica
Full text is only aviable in PDF
Bibliography
[1.]
R.A. Bernarda.
Cancro: Cronologia histórica e génese de ideias. Faculdade de Medicina da Universidade de Coimbra.
Gráfica da Lousã, (1996),
[2.]
L. Kreyberg.
Histological lung cancer types.
Acta Pathologica e Microbiologica Scandinavica, 157 (1962), pp. 1-93
[3.]
Kreyberg L, Liebow AA, Uehlinger EA. Histological typing of lung tumours. Geneva, World Health Organization 1969. International Histological Classification of Tumours, n.° 1.
[4.]
The World Health Organization histological typing of lung tumours.
Am J Clin Pathol, 77 (1982), pp. 123-136
[5.]
W. Travis, E. Brambilla, H.K. Muller-Hermelink, C. Harris.
Tumours of the lung, pleura, thymus and heart Pathology and Genetics. World Health Organization Classification of Tumours.
IARCPress, (2004),
[6.]
Y. Sakao, H. Miyamoto, S. Oh, et al.
The impact of cigarette smoking on prognosis in small adenocarcinomas of the lung: the association between histologic subtype and smoking status.
J Thorac Oncol, 3 (2008), pp. 958-962
[7.]
C.Q. Zhu, S.G. da Cunha, K. Ding, et al.
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
J Clin Oncol, 26 (2008), pp. 4268-4275
[8.]
F.R. Hirsch, R.S. Herbst, C. Olsen, et al.
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.
J Clin Oncol, 26 (2008), pp. 3351-3357
[9.]
L. Carvalho, E. Cardoso, H. Nunes, V. Baptista, A. Gomes, P. Couceiro.
Projecto de estadiamento do cancro do pulmão pela IASLC: Estudo comparativo entre a 6.ª edi ção TNM em vigor e a 7.ª edição proposta.
Rev Port Pneumol, 15 (2009), pp. 67-76
[10.]
M. Varella-Garcia, T. Mitsudomi, Y. Yatabe, T. Kosaka, et al.
EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery.
J Thorac Oncol, 4 (2009), pp. 318-325
[11.]
P. Seve, R. Lai, K. Ding, et al.
Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR 10.
Clin Cancer Res, 13 (2007), pp. 994-999
[12.]
P. Seve, T. Reiman, R. Lai, et al.
Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
Cancer Chemother Pharmacol, 60 (2007), pp. 27-34
[13.]
S.M. Hewitt, F.A. Lewis, Y. Cao, et al.
Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue.
Arch Pathol Lab Med, 132 (2008), pp. 1929-1935
[14.]
E. Giovannetti, V. Mey, S. Nannizzi, et al.
Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells.
Mol Pharmacol, 68 (2005), pp. 110-118
[15.]
J.R. Izbicki, B. Passlick, S.B. Hosch, et al.
Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis.
J Thorac Cardiovasc Surg, 112 (1996), pp. 623-630
[16.]
P. Ceppi, M. Volante, S. Saviozzi, et al.
Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase.
Cancer, 107 (2006), pp. 1589-1596
[17.]
L. Carvalho.
Wild type of exons 19 and 21 and polysomy of chromosome 7 were defined for EGFR gene in squamous cell carcinoma of the lung.
Journal of Thoracic Oncology, 3 (2008), pp. S35-S36
[18.]
V. Sousa, M. Silva, A. Alarcão, P. Couceiro, A. Gomes, L. Carvalho.
Squamous cell carcinoma of the lung: polysomy of chromosome 7 and wild type of exon 19 and 21 were defined for EGFR gene.
Virchows Archiv, 452 (2008), pp. S1
[19.]
V. Boggaram.
Thyroid transcription factor-1 (TTF-1/Nkx2. 1/TITF1) gene regulation in the lung.
Clin Sci (Lond), 116 (2009), pp. 27-35
[20.]
A. Araujo, F. Barata, B. Parente, et al.
Pemetrexed in second line treatment of non-small cell lung cancer.
The Portuguese experience. Rev Port Pneumol, XIV (2008), pp. S9-S20
[21.]
K.M. Kerr.
Pathologist and molecular biologist, ever the twain shall meet?.
Lung Cancer, 63 (2009), pp. 161-163
[22.]
A.M. Oliveira, H.D. Tazelaar, J.L. Myers, L.A. Erickson, R.V. Lloyd.
Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites.
Am J Surg Pathol, 25 (2001), pp. 815-819
[23.]
M.I. Ramirez, A.K. Rishi, Y.X. Cao, M.C. Williams.
TGT3, thyroid transcription factor I, and Sp1 elements regulate transcriptional activity of the 1.3-kilobase pair promoter of T1alpha, a lung alveolar type I cell gene.
J Biol Chem, 272 (1997), pp. 285-326
[24.]
E.S. Ngan, B.H. Lang, T. Liu, et al.
A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
J Natl Cancer Inst, 101 (2009), pp. 162-175
[25.]
H. Ninomiya, M. Hiramatsu, K. Inamura, et al.
Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type.
Lung Cancer, 63 (2009), pp. 235-240
[26.]
M. Nakazato, H.K. Chung, L. Ulianich, A. Grassadonia, K. Suzuki, L.D. Kohn.
Thyroglobulin repression of thyroid transcription factor 1 (TTF-1) gene expression is mediated by decreased DNA binding of nuclear factor I proteins which control constitutive TTF-1 expression.
Mol Cell Biol, 20 (2000), pp. 8499-8512
[27.]
N. Motoi, J. Szoke, G.J. Riely, et al.
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes EGFR mutations and gene expression analysis.
Am J Surg Pathol, 32 (2008), pp. 810-827
[28.]
K. Kerr.
Pulmonary adenocarcinomas: classification and reporting.
Histopathology, 54 (2009), pp. 27
[29.]
R. Ullman, M. Bongiovanni, I. Halbwedl, S. Petzmann, M. Gogg-Kammerer, A. Sapino, M. Papotti, G. Bussolati, H. Popper.
Bronchiolar columnar cell dysplasia-genetic analysis of a novel preneoplastic lesion of peripheral lung.
Virchows Archiv, 442 (2003), pp. 429-436
[30.]
S. Lantuéjul, D. Salameire, C. Salon, E. Brambilla.
Pulmonary preneoplasia . sequential molecular carcinogenetic events.
Histopathology, 54 (2009), pp. 43-54
[31.]
M. Noguchi, A. Morikawa, M. Kawasaki, et al.
Small adenocarcinoma of the lung Histologic characteristics and prognosis.
Cancer, 75 (1995), pp. 2844-2852
[32.]
S.A. Silver, F.B. Askin.
True papillary carcinoma of the lung: a distinct clinicopathologic entity.
Am J Surg Pathol, 21 (1997), pp. 43-51
[33.]
V.K. Anagnostou, K.N. Syrigos, G. Bepler, R.J. Homer, D.L. Rimm.
Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma.
J Clin Oncol, 27 (2009), pp. 271-278
[34.]
M. Noguchi, Y. Minami, T. Iijima, Y. Matsuno.
Reproducibility. of the diagnosis of small adenocarcinoma of the lung and usefulness of an educational program for the diagnostic criteria.
Pathol Int, 55 (2005), pp. 8-13
[35.]
A. Sakurada, M.S. Tsao.
Predictive biomarkers for EGFR therapy.
I Drugs, 12 (2009), pp. 34-38
[36.]
N.S. Goldstein, A. Mani, G. Chmielewski, R. Welsh, S. Pursel.
Immunohistochemically detected micrometastases in peribronchial and mediastinal lymph nodes from patients with T1, N0 M0 pulmonary adenocarcinomas.
Am J Surg Pathol, 24 (2000), pp. 274-279
[37.]
J. Pohlenz, A. Dumitrescu, D. Zundel, et al.
Partial deficiency of thyroid transcription factor 1 produces predominantly neurological defects in humans and mice.
J Clin Invest, 109 (2002), pp. 469-473
[38.]
B. Parente.
Mesothelioma treatment.
Rev Port Pneumol, XIV (2008), pp. S35-S44
[39.]
M.V. Brock, C.M. Hooker, E. Ota-Machida, et al.
DNA methylation markers and early recurrence in stage I lung cancer.
N Engl J Med, 358 (2008), pp. 1118-1128
[40.]
M.B. Beasly.
Immunohistochemistry of pulmonary and pleural neoplasia.
Arch Pathol Lab Med, 132 (2008), pp. 1062-1072
[41.]
B. Addis, H. Roche.
Problems in mesothelioma diagnosis.
Histopathology, 54 (2009), pp. 55-68
[42.]
H. Terasaki, T. Niki, Y. Matsuno, et al.
Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization.
Am J Surg Pathol, 27 (2003), pp. 937-951
[43.]
D.A. Eberhard, G. Giaccone, B.E. Johnson.
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-small-cell lung cancer working group: standardization for use in the clinical trial setting.
J Clin Oncol, 26 (2008), pp. 983-994
[44.]
H. Suehisa, S. Toyooka, K. Hotta, et al.
Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.
J Clin Oncol, 25 (2007), pp. 3952-3957
[45.]
Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, G. Bepler.
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.
N Engl J Med, 356 (2007), pp. 800-808
[46.]
M.S. Tsao, S. Viel-Ronen, K. Ding, et al.
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
J Clin Oncol, 25 (2007), pp. 5240-5247
[47.]
K.A. Olaussen, A. Dunant, P. Fouret, et al.
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
N Engl J Med, 355 (2006), pp. 983-991
[48.]
G. Bepler, I. Kusmartseva, S. Sharma, et al.
RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.
J Clin Oncol, 24 (2006), pp. 4731-4737
[49.]
G. Sica, P.L. Wagner, N. Altorki, et al.
Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors.
Arch Pathol Lab Med, 132 (2008), pp. 1889-1895
[50.]
C. Moran, S. Suster, D. Coppola, M. Wick.
Neuroendocrine carcinomas of the lung.
Am J Clin Pathol, 131 (2009), pp. 206-221
[51.]
G. Fellegara, T. D’Adda, F.P. Pilato, et al.
Genetics of a combined lung small cell carcinoma and large cell neuroendocrine carcinoma with adenocarcinoma.
Virchows Arch, 453 (2008), pp. 107-115
[52.]
P. Wagner, N. Kitabayashi, Y.T. Chen, A. Saqi.
Combined small cell lung carcinoma.
Am J Clin Pathol, 131 (2009), pp. 376-382
[53.]
P. Ferolla, N. Daddi, M. Urbani, A. Semeraro, et al.
Tumorlets, multicentric carcinoids, lymph-nodal metástases and long term behaviour in bronchial carcinoids.
Journal of Thoracic Oncology, 4 (2009), pp. 383-387
[54.]
A. Wurtz, L. Benhamed, M. Conti, B. Bouchindhomme, H. Porte.
Results of systematic nodal dissection in typical nad atypical carcinoid tumors of the lung.
Journal of Thoracic Oncology, 4 (2009), pp. 388-394
[55.]
C. Gomez-Fernandez, M. Jorda, P.I. Delgado, P. Ganjei-Azar.
Thyroid transcription factor 1: a marker for lung adenoarinoma in body cavity fluids.
Cancer, 96 (2002), pp. 289-293
[56.]
S. Miccadei, L.R. De, E. Zammarchi, P.G. Natali, D. Civitareale.
The synergistic activity of thyroid transcription factor 1 and Pax 8 relies on the promoter/enhancer interplay.
Mol Endocrinol, 16 (2002), pp. 837-846
[57.]
R. Rosell, E. Felip, L. Paz-Ares.
How could pharmacogenomics help improve patient survival?.
Lung Cancer, 57 (2007), pp. S35-S41
[58.]
W. Wallace.
The challenge of classifying poorly differentiated tumours of the lung.
Histopathology, 54 (2009), pp. 28-42
[59.]
A.R. Hanauske, U. Eismann, O. Oberschmidt, et al.
In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression.
Invest New Drugs, 25 (2007), pp. 417-423
[60.]
S. Yendamuri, A.A. Vaporciyan, T. Zaidi, et al.
3p22.1 and 10q22.3 deletions detected by fluorescence in situ hybridization (FISH): a potential new tool for early detection of non-small cell lung Cancer (NSCLC).
J Thorac Oncol, 3 (2008), pp. 979-984
[61.]
V.P. Hespanhol.
Lung câncer treatment Biology based decision, from gene to histology.
Rev Port Pneumol, XIV (2008), pp. S27-S34
[62.]
F. Barata.
Pemetrexed in second line of non-small cell lung cancer.
Rev Port Pneumol, XIV (2008), pp. S21-S26
[63.]
C. Edwards.
Pulmonary adenocarcinoma: review of 106 cases and proposed new classification.
J Clin Pathol, 40 (1987), pp. 125-135
[64.]
J. Rosai.
Evidence-based pathology and the pathologic evaluation of thymomas.
Arch Pathol Lab Med, 132 (2008), pp. 1859
[65.]
L. Zhong, J. Roybal, R. Chaerkady, et al.
Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment.
Cancer Res, 68 (2008), pp. 7237-7245
[66.]
P. Seve, C. Dumontet.
Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?.
Lancet Oncol, 9 (2008), pp. 168-175
[67.]
T. Donnem, S. Al-Saad, K. Al-Shibli, S. Andersen, L.T. Busund, R.M. Bremnes.
Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells.
J Thorac Oncol, 3 (2008), pp. 963-970
[68.]
K. Crysam, J. Lee, M. Dohadwala, B. Gardner, et al.
Inflammation, epithelial to mesenchimal transition and epidermal growth factor receptor tyrosine kinase inhibitor resistence.
J Thorac Oncol, 3 (2008), pp. 107-110
[69.]
R.S. Herbst, S.M. Lippman.
Molecular signatures of lung cancer-toward personalized therapy.
N Engl J Med, 356 (2007), pp. 76-78
[70.]
F. Cappuzzo, C. Ligorio, P.A. Janne, et al.
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
J Clin Oncol, 25 (2007), pp. 2248-2255
[71.]
M. Filipits, R. Pirker, A. Dunant, et al.
Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
J Clin Oncol, 25 (2007), pp. 2735-2740
[72.]
G.V. Scagliotti, P. Parikh, P.J. Von, et al.
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
J Clin Oncol, 26 (2008), pp. 3543-3551
[73.]
R.S. Herbst, J.V. Heymach, S.M. Lippman.
Lung cancer.
N Engl J Med, 359 (2008), pp. 1367-1380
[74.]
S. Maheswaran, L.V. Sequist, S. Nagrath, et al.
Detection of mutations in EGFR in circulating lung-cancer cells.
N Engl J Med, 359 (2008), pp. 366-377
[75.]
S.K. Lau, P.C. Boutros, M. Pintilie, et al.
Three-gene prognostic classifier for early-stage non small-cell lung cancer.
J Clin Oncol, 25 (2007), pp. 5562-5569
[76.]
A.F. Gazdar.
DNA repair and survival in lung cancer – the two faces of Janus.
N Engl J Med, 356 (2007), pp. 771-773
[77.]
M. Togni, S. Eber, J. Widmer, et al.
Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial.
J Am Coll Cardiol, 50 (2007), pp. 1123-1131
[78.]
D. Ornish, J. Lin, J. Daubenmier, et al.
Increased telomerase activity and comprehensive lifestyle changes: A pilot study.
Lancet Oncol, 9 (2008), pp. 1048-1057
[79.]
T. Kawakami, K. Nabeshima, M. Hamasaki, A. Iwasaki, T. Shirakusa, H. Iwasaki.
Small cluster invasion: a possible link between micropapillary pattern and lymph node metastasis in pT1 lung adenocarcinomas.
Virchows Archiv, 454 (2009), pp. 61-70
[80.]
J. Borgia, S. Basu, L. Faber, A. Kim, et al.
Establishment of a multy-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer.
J Thorac Oncol, 4 (2009), pp. 338-347
Copyright © 2009. Sociedade Portuguesa de Pneumologia
